{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:03:36Z","timestamp":1781870616401,"version":"3.54.5"},"reference-count":74,"publisher":"American Institute of Mathematical Sciences (AIMS)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.3934\/microbiol.2021007","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T13:54:32Z","timestamp":1612792472000},"page":"96-113","source":"Crossref","is-referenced-by-count":18,"title":["Bacillus Calmette-Guerin (BCG): the adroit vaccine"],"prefix":"10.3934","volume":"7","author":[{"given":"Oluwafolajimi A.","family":"Adesanya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Institute for Advanced Medical Research and Training (IAMRAT), College of Medicine, University of Ibadan, Ibadan, Nigeria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christabel I.","family":"Uche-Orji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeshua A.","family":"Adedeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John I.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeniyi A.","family":"Adesola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chibuike J.","family":"Chukwudike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2321","reference":[{"key":"key-10.3934\/microbiol.2021007-1","unstructured":"Luca S, Mihaescu T (2013) History of BCG vaccine.&nbsp;<i>Maedica (Buchar)<\/i>&nbsp;8: 53-58."},{"key":"key-10.3934\/microbiol.2021007-2","doi-asserted-by":"crossref","unstructured":"Ben\u00e9volo-de-Andrade TC, Monteiro-Maia R, Cosgrove C, et al. (2005) BCG Moreau Rio de Janeiro-An oral vaccine against tuberculosis-review.&nbsp;<i>Mem Inst Oswaldo Cruz<\/i>&nbsp;100: 459-465.","DOI":"10.1590\/S0074-02762005000500002"},{"key":"key-10.3934\/microbiol.2021007-3","doi-asserted-by":"crossref","unstructured":"Dagg B, Hockley J, Rigsby P, et al. (2014) &nbsp;<i>The establishment of sub-strain specific WHO Reference Reagents for BCG vaccine<\/i>&nbsp;32: 6390-6395.","DOI":"10.1016\/j.vaccine.2014.09.065"},{"key":"key-10.3934\/microbiol.2021007-4","doi-asserted-by":"crossref","unstructured":"Comstock G (1994) The International tuberculosis campaign: a pioneering venture in mass vaccination and research.&nbsp;<i>Clin Infect Dis<\/i>&nbsp;19: 528-540.","DOI":"10.1093\/clinids\/19.3.528"},{"key":"key-10.3934\/microbiol.2021007-5","doi-asserted-by":"crossref","unstructured":"Zwerling A, Behr MA, Verma A, et al. (2011) The BCG World Atlas: A database of global BCG vaccination policies and practices.&nbsp;<i>PLoS Med<\/i>&nbsp;8: e1001012.","DOI":"10.1371\/journal.pmed.1001012"},{"key":"key-10.3934\/microbiol.2021007-6","doi-asserted-by":"crossref","unstructured":"Trunz BB, Fine P, Dye C (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness.&nbsp;<i>Lancet<\/i>&nbsp;367: 1173-1180.","DOI":"10.1016\/S0140-6736(06)68507-3"},{"key":"key-10.3934\/microbiol.2021007-7","unstructured":"Awasthi S, Moin S (1999) Effectiveness of BCG vaccination against tuberculous meningitis.&nbsp;<i>Indian Pediatr<\/i>&nbsp;36: 455-460."},{"key":"key-10.3934\/microbiol.2021007-8","unstructured":"Mangtani P, Abubakar I, Ariti C, et al. (2013) Protection by BCG vaccine against Tuberculosis: a systematic review of randomized controlled trials.&nbsp;<i>Clin Infect Dis<\/i>&nbsp;58: 470-80."},{"key":"key-10.3934\/microbiol.2021007-9","doi-asserted-by":"crossref","unstructured":"Setia MS, Steinmaus C, Ho CS, et al. (2006) The role of BCG in prevention of leprosy: A meta-analysis.&nbsp;<i>Lancet Infect Dis<\/i>&nbsp;6: 162-170.","DOI":"10.1016\/S1473-3099(06)70412-1"},{"key":"key-10.3934\/microbiol.2021007-10","doi-asserted-by":"crossref","unstructured":"Shann F (2013) Nonspecific effects of vaccines and the reduction of mortality in children.&nbsp;<i>Clin Ther<\/i>&nbsp;35: 109-114.","DOI":"10.1016\/j.clinthera.2013.01.007"},{"key":"key-10.3934\/microbiol.2021007-11","doi-asserted-by":"crossref","unstructured":"Shann F (2010) The non-specific effects of vaccines.&nbsp;<i>Arch Dis Child<\/i>&nbsp;95: 662-667.","DOI":"10.1136\/adc.2009.157537"},{"key":"key-10.3934\/microbiol.2021007-12","unstructured":"Kristensen I, Aaby P, Jensen H (2000) Routine vaccinations and child survival: Follow up study in Guinea-Bissau, West Africa.&nbsp;<i>Br Med J<\/i>&nbsp;321: 1435-1439."},{"key":"key-10.3934\/microbiol.2021007-13","doi-asserted-by":"crossref","unstructured":"Roth A, Gustafson P, Nhaga A, et al. (2005) BCG vaccination scar associated with better childhood survival in Guinea-Bissau.&nbsp;<i>Int J Epidemiol<\/i>&nbsp;34: 540-547.","DOI":"10.1093\/ije\/dyh392"},{"key":"key-10.3934\/microbiol.2021007-14","doi-asserted-by":"crossref","unstructured":"Garly ML, Martins CL, Bal\u00e9 C, et al. (2003) BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa: A non-specific beneficial effect of BCG?&nbsp;<i>Vaccine<\/i>&nbsp;21: 2782-2790.","DOI":"10.1016\/S0264-410X(03)00181-6"},{"key":"key-10.3934\/microbiol.2021007-15","doi-asserted-by":"crossref","unstructured":"Biering-S\u00f8rensen S, Aaby P, Lund N, et al. (2017) Early BCG-Denmark and neonatal mortality among infants weighing &lt;2500 g: A randomized controlled trial.&nbsp;<i>Clin Infect Dis<\/i>&nbsp;65: 1183-1190.","DOI":"10.1093\/cid\/cix525"},{"key":"key-10.3934\/microbiol.2021007-16","doi-asserted-by":"crossref","unstructured":"Nankabirwa V, Tumwine JK, Mugaba PM, et al. (2015) Child survival and BCG vaccination: A community based prospective cohort study in Uganda.&nbsp;<i>BMC Public Health<\/i>&nbsp;15: 175.","DOI":"10.1186\/s12889-015-1497-8"},{"key":"key-10.3934\/microbiol.2021007-17","doi-asserted-by":"crossref","unstructured":"Zimmermann P, Finn A, Curtis N (2018) Does BCG vaccination protect against nontuberculous mycobacterial infection? A systematic review and meta-analysis.&nbsp;<i>J Infect Dis<\/i>&nbsp;218: 679-687.","DOI":"10.1093\/infdis\/jiy207"},{"key":"key-10.3934\/microbiol.2021007-18","doi-asserted-by":"crossref","unstructured":"Aaby P, Roth A, Ravn H, et al. (2011) Randomized Trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?&nbsp;<i>J Infect Dis<\/i>&nbsp;204: 245-252.","DOI":"10.1093\/infdis\/jir240"},{"key":"key-10.3934\/microbiol.2021007-19","doi-asserted-by":"crossref","unstructured":"Biering-S\u00f8rensen S, Aaby P, Napirna BM, et al. (2012) Small randomized trial among low-birth-weight children receiving bacillus Calmette-Gu\u00e9erin vaccination at first health center contact.&nbsp;<i>Pediatr Infect Dis J<\/i>&nbsp;31: 306-308.","DOI":"10.1097\/INF.0b013e3182458289"},{"key":"key-10.3934\/microbiol.2021007-20","doi-asserted-by":"crossref","unstructured":"Stensballe LG, S\u00f8rup S, Aaby P, et al. (2017) BCG vaccination at birth and early childhood hospitalisation: A randomised clinical multicentre trial.&nbsp;<i>Arch Dis Child<\/i>&nbsp;102: 224-231.","DOI":"10.1136\/archdischild-2016-310760"},{"key":"key-10.3934\/microbiol.2021007-21","unstructured":"Stensballe LG, Nante E, Jensen IP, et al. (2005) Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: A beneficial effect of BCG vaccination for girls: Community based case-control study.&nbsp;<i>Vaccine<\/i>&nbsp;23: 1251-1257."},{"key":"key-10.3934\/microbiol.2021007-22","unstructured":"Wardhana, Datau E, Sultana A, et al. (2011) The efficacy of Bacillus Calmette-Gu\u00e9rin vaccinations for the prevention of acute upper respiratory tract infection in the elderly.&nbsp;<i>Acta Med Indones<\/i>&nbsp;43: 185-190."},{"key":"key-10.3934\/microbiol.2021007-23","unstructured":"Ohrui T, Nakayama K, Fukushima T, et al. (2005) Prevention of elderly pneumonia by pneumococcal, influenza and BCG vaccinations.&nbsp;<i>Japanese J Geriatr<\/i>&nbsp;42: 34-36."},{"key":"key-10.3934\/microbiol.2021007-24","doi-asserted-by":"crossref","unstructured":"Salem A, Nofal A, Hosny D (2013) Treatment of common and plane warts in children with topical viable bacillus calmette-guerin.&nbsp;<i>Pediatr Dermatol<\/i>&nbsp;30: 60-63.","DOI":"10.1111\/j.1525-1470.2012.01848.x"},{"key":"key-10.3934\/microbiol.2021007-25","unstructured":"Podder I, Bhattacharya S, Mishra V, et al. (2017) Immunotherapy in viral warts with intradermal Bacillus Calmette-Guerin vaccine versus intradermal tuberculin purified protein derivative: A double-blind, randomized controlled trial comparing effectiveness and safety in a tertiary care center in Eastern India.&nbsp;<i>Indian J Dermatol Venereol Leprol<\/i>&nbsp;83: 411."},{"key":"key-10.3934\/microbiol.2021007-26","doi-asserted-by":"crossref","unstructured":"Daulatabad D, Pandhi D, Singal A (2016) BCG vaccine for immunotherapy in warts: is it really safe in a tuberculosis endemic area?&nbsp;<i>Dermatol Ther<\/i>&nbsp;29: 168-172.","DOI":"10.1111\/dth.12336"},{"key":"key-10.3934\/microbiol.2021007-27","doi-asserted-by":"crossref","unstructured":"Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors.&nbsp;<i>J Urol<\/i>&nbsp;116: 180-182.","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"key-10.3934\/microbiol.2021007-28","unstructured":"Jackson A, James K (1994) Understanding the most successful immunotherapy for cancer.&nbsp;<i>Immunol<\/i>&nbsp;2: 208-215."},{"key":"key-10.3934\/microbiol.2021007-29","doi-asserted-by":"crossref","unstructured":"Prescott S, James K, Busuttil A, et al. (1989) HLA\u2014DR Expression by High Grade Superficial Bladder Cancer Treated with BCG.&nbsp;<i>Br J Urol<\/i>&nbsp;63: 264-269.","DOI":"10.1111\/j.1464-410X.1989.tb05187.x"},{"key":"key-10.3934\/microbiol.2021007-30","doi-asserted-by":"crossref","unstructured":"Jackson AM, Alexandroff AB, McIntyre M, et al. (1994) Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy.&nbsp;<i>J Clin Pathol<\/i>&nbsp;47: 309-312.","DOI":"10.1136\/jcp.47.4.309"},{"key":"key-10.3934\/microbiol.2021007-31","unstructured":"Meyer J-P, Persad R (2002) Use of bacille Calmette-Gu\u00e9rin in superficial bladder cancer.&nbsp;<i>Postgrad Med J<\/i>&nbsp;78."},{"key":"key-10.3934\/microbiol.2021007-32","doi-asserted-by":"crossref","unstructured":"Leentjens J, Kox M, Stokman R, et al. (2015) BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: A randomized, placebo-controlled pilot study.&nbsp;<i>J Infect Dis<\/i>&nbsp;212: 1930-1938.","DOI":"10.1093\/infdis\/jiv332"},{"key":"key-10.3934\/microbiol.2021007-33","doi-asserted-by":"crossref","unstructured":"Ritz N, Mui M, Balloch A, et al. (2013) Non-specific effect of Bacille Calmette-Gu\u00e9rin vaccine on the immune response to routine immunisations.&nbsp;<i>Vaccine<\/i>&nbsp;31: 3098-3103.","DOI":"10.1016\/j.vaccine.2013.03.059"},{"key":"key-10.3934\/microbiol.2021007-34","unstructured":"Ota MOC, Vekemans J, Schlegel-Haueter SE, et al. (2002) Influence of Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin on antibody and cytokine responses to human neonatal vaccination.&nbsp;<i>J Immunol<\/i>&nbsp;168: 919-925."},{"key":"key-10.3934\/microbiol.2021007-35","doi-asserted-by":"crossref","unstructured":"Scheid A, Borriello F, Pietrasanta C, et al. (2018) Adjuvant effect of Bacille Calmette-Gu\u00e9rin on hepatitis B vaccine immunogenicity in the preterm and term newborn.&nbsp;<i>Front Immunol<\/i>&nbsp;9: 29.","DOI":"10.3389\/fimmu.2018.00029"},{"key":"key-10.3934\/microbiol.2021007-36","doi-asserted-by":"crossref","unstructured":"Arts RJW, Moorlag SJCFM, Novakovic B, et al. (2018) BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity.&nbsp;<i>Cell Host Microbe<\/i>&nbsp;23: 89-100.","DOI":"10.1016\/j.chom.2017.12.010"},{"key":"key-10.3934\/microbiol.2021007-37","unstructured":"FD A, RN U, CL L (1974) Recurrent herpes genitalis. Treatment with Mycobacterium bovis (BCG).&nbsp;<i>Obs Gynecol<\/i>&nbsp;43: 797-805."},{"key":"key-10.3934\/microbiol.2021007-38","unstructured":"Hippmann G, Wekkeli M, Rosenkranz A, et al. (1992) Nonspecific immune stimulation with BCG in Herpes simplex recidivans. Follow-up 5 to 10 years after BCG vaccination.&nbsp;<i>Wien Klin Wochenschr<\/i>&nbsp;104: 200-204."},{"key":"key-10.3934\/microbiol.2021007-39","doi-asserted-by":"crossref","unstructured":"Ahmed SS, Volkmuth W, Duca J, et al. (2015) Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.&nbsp;<i>Sci Transl Med<\/i>&nbsp;7.","DOI":"10.1126\/scitranslmed.aab2354"},{"key":"key-10.3934\/microbiol.2021007-40","unstructured":"Su LF, Kidd BA, Han A, et al. (2013) Virus-Specific CD4+ Memory-Phenotype T Cells Are Abundant in Unexposed Adults.&nbsp;<i>Immunity<\/i>&nbsp;38: 373-383."},{"key":"key-10.3934\/microbiol.2021007-41","doi-asserted-by":"crossref","unstructured":"Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological memory by polyclonal activation of human memory B cells.&nbsp;<i>Science<\/i>&nbsp;298: 2199-2202.","DOI":"10.1126\/science.1076071"},{"key":"key-10.3934\/microbiol.2021007-42","doi-asserted-by":"crossref","unstructured":"Kleinnijenhuis J, Quintin J, Preijers F, et al. (2014) Long-lasting effects of bcg vaccination on both heterologous th1\/th17 responses and innate trained immunity.&nbsp;<i>J Innate Immun<\/i>&nbsp;6: 152-158.","DOI":"10.1159\/000355628"},{"key":"key-10.3934\/microbiol.2021007-43","unstructured":"Vetskova EK, Muhtarova MN, Avramov TI, et al. (2013) Immunomodulatory effects of BCG in patients with recurrent respiratory papillomatosis.&nbsp;<i>Folia Med<\/i>&nbsp;55: 49-54."},{"key":"key-10.3934\/microbiol.2021007-44","doi-asserted-by":"crossref","unstructured":"Mathurin KS, Martens GW, Kornfeld H, et al. (2009) CD4 T-Cell-Mediated Heterologous Immunity between Mycobacteria and Poxviruses.&nbsp;<i>J Virol<\/i>&nbsp;83: 3528-39.","DOI":"10.1128\/JVI.02393-08"},{"key":"key-10.3934\/microbiol.2021007-45","doi-asserted-by":"crossref","unstructured":"Kandasamy R, Voysey M, McQuaid F, et al. (2016) Non-specific immunological effects of selected routine childhood immunisations: Systematic review.&nbsp;<i>BMJ<\/i>&nbsp;355.","DOI":"10.1136\/bmj.i5225"},{"key":"key-10.3934\/microbiol.2021007-46","doi-asserted-by":"crossref","unstructured":"Netea MG, Joosten LAB, Latz E, et al. (2016) Trained immunity: A program of innate immune memory in health and disease.&nbsp;<i>Science<\/i>&nbsp;352: 427.","DOI":"10.1126\/science.aaf1098"},{"key":"key-10.3934\/microbiol.2021007-47","doi-asserted-by":"crossref","unstructured":"Kleinnijenhuis J, Quintin J, Preijers F, et al. (2012) Bacille Calmette-Gu\u00e9rin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes.&nbsp;<i>Proc Natl Acad Sci USA<\/i>&nbsp;109: 17537-17542.","DOI":"10.1073\/pnas.1202870109"},{"key":"key-10.3934\/microbiol.2021007-48","unstructured":"Rathinam VAK, Fitzgerald KA (2010) Inflammasomes and anti-viral immunity.&nbsp;<i>J Clin Immunol<\/i>&nbsp;30: 632-637."},{"key":"key-10.3934\/microbiol.2021007-49","doi-asserted-by":"crossref","unstructured":"Allen IC, Scull MA, Moore CB, et al. (2009) The NLRP3 inflammasome mediates <i>in vivo<\/i> innate immunity to influenza a virus through recognition of viral RNA.&nbsp;<i>Immunity<\/i>&nbsp;30: 556-565.","DOI":"10.1016\/j.immuni.2009.02.005"},{"key":"key-10.3934\/microbiol.2021007-50","doi-asserted-by":"crossref","unstructured":"Thomas PG, Dash P, Aldridge JR, et al. (2009) The intracellular sensor NLRP3 mediates key innate and healing responses to influenza a virus via the regulation of Caspase-1.&nbsp;<i>Immunity<\/i>&nbsp;30: 566-575.","DOI":"10.1016\/j.immuni.2009.02.006"},{"key":"key-10.3934\/microbiol.2021007-51","doi-asserted-by":"crossref","unstructured":"Wu F, Zhao S, Yu B, et al. (2020) A new coronavirus associated with human respiratory disease in China.&nbsp;<i>Nature<\/i>&nbsp;579: 265-269.","DOI":"10.1038\/s41586-020-2008-3"},{"key":"key-10.3934\/microbiol.2021007-52","doi-asserted-by":"crossref","unstructured":"Miller A, Reandelar MJ, Fasciglione K, et al.&nbsp;Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study (2020) .","DOI":"10.1101\/2020.03.24.20042937"},{"key":"key-10.3934\/microbiol.2021007-53","doi-asserted-by":"crossref","unstructured":"Scheid A, Borriello F, Pietrasanta C, et al. (2018) Adjuvant effect of Bacille Calmette-Gu\u00e9rin on hepatitis B vaccine immunogenicity in the preterm and term newborn.&nbsp;<i>Front Immunol<\/i>&nbsp;9: 24.","DOI":"10.3389\/fimmu.2018.00029"},{"key":"key-10.3934\/microbiol.2021007-54","doi-asserted-by":"crossref","unstructured":"Sato H, Jing C, Isshiki M, et al. (2013) Immunogenicity and safety of the vaccinia virus LC16m8\u03b4 vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol.&nbsp;<i>Vaccine<\/i>&nbsp;31: 3549-3557.","DOI":"10.1016\/j.vaccine.2013.05.071"},{"key":"key-10.3934\/microbiol.2021007-55","doi-asserted-by":"crossref","unstructured":"Yazdanian M, Memarnejadian A, Mahdavi M, et al. (2013) Immunization of mice by BCG formulated HCV core protein elicited higher th1-oriented responses compared to pluronic-F127 copolymer.&nbsp;<i>Hepat Mon<\/i>&nbsp;13.","DOI":"10.5812\/hepatmon.14178"},{"key":"key-10.3934\/microbiol.2021007-56","doi-asserted-by":"crossref","unstructured":"Kim BJ, Kim BR, Kook YH, et al. (2018) Development of a live recombinant BCG expressing human immunodeficiency virus type 1 (HIV-1) gag using a pMyong2 vector system: Potential use as a novel HIV-1 vaccine.&nbsp;<i>Front Immunol<\/i>&nbsp;9: 27.","DOI":"10.3389\/fimmu.2018.00643"},{"key":"key-10.3934\/microbiol.2021007-57","doi-asserted-by":"crossref","unstructured":"Zhou P, Yang X Lou, Wang XG, et al. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin.&nbsp;<i>Nature<\/i>&nbsp;579: 270-273.","DOI":"10.1038\/s41586-020-2012-7"},{"key":"key-10.3934\/microbiol.2021007-58","doi-asserted-by":"crossref","unstructured":"Adesanya OA, Adewale BA, Ebengho IG, et al. (2020) Current knowledge on the pathogenesis of and therapeutic options against SARS-CoV-2: An extensive review of the available evidence.&nbsp;<i>Int J Pathog Res<\/i>&nbsp;4: 16-36.","DOI":"10.9734\/ijpr\/2020\/v4i230108"},{"key":"key-10.3934\/microbiol.2021007-59","unstructured":"Johns Hopkins&nbsp;COVID-19 Map-Johns Hopkins Coronavirus Resource Center (2020) .Available from: <a a-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" href=\"https:\/\/coronavirus.jhu.edu\/map.html\">https:\/\/coronavirus.jhu.edu\/map.html<\/a>."},{"key":"key-10.3934\/microbiol.2021007-60","unstructured":"Hegarty PK, Service NH, Kamat AM, et al. (2020) BCG vaccination may be protective against Covid-19.&nbsp;<i>medRxiv<\/i>&nbsp;(March)."},{"key":"key-10.3934\/microbiol.2021007-61","doi-asserted-by":"crossref","unstructured":"Dayal D, Gupta S (2020) Connecting BCG Vaccination and COVID-19: Additional Data.&nbsp;<i>medRxiv<\/i>&nbsp;(April).","DOI":"10.1101\/2020.04.07.20053272"},{"key":"key-10.3934\/microbiol.2021007-62","doi-asserted-by":"crossref","unstructured":"Dolgikh S (2020) Further Evidence of a Possible Correlation between the Severity of Covid-19 and BCG Immunization.&nbsp;<i>J Infect Dis Epidemiol<\/i>&nbsp;6.","DOI":"10.1101\/2020.04.07.20056994"},{"key":"key-10.3934\/microbiol.2021007-63","doi-asserted-by":"crossref","unstructured":"Sharma A, Kumar Sharma S, Shi Y, et al. (2020) BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?&nbsp;<i>Cell Death Dis<\/i>&nbsp;11: 516.","DOI":"10.1038\/s41419-020-2720-9"},{"key":"key-10.3934\/microbiol.2021007-64","doi-asserted-by":"crossref","unstructured":"Ebina-Shibuya R, Horita N, Namkoong H, et al. (2020) National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19.&nbsp;<i>Respirology<\/i>&nbsp;25: 898-899.","DOI":"10.1111\/resp.13885"},{"key":"key-10.3934\/microbiol.2021007-65","doi-asserted-by":"crossref","unstructured":"Kinoshita M, Tanaka M (2020) Impact of Routine Infant BCG Vaccination on COVID-19.&nbsp;<i>J Infect<\/i>&nbsp;81: 625-633.","DOI":"10.1016\/j.jinf.2020.08.013"},{"key":"key-10.3934\/microbiol.2021007-66","doi-asserted-by":"crossref","unstructured":"Klinger D, Blass I, Rappoport N, et al. (2020) Significantly improved COVID-19 outcomes in countries with higher bcg vaccination coverage: A multivariable analysis.&nbsp;<i>Vaccines<\/i>&nbsp;8: 1-14.","DOI":"10.3390\/vaccines8030378"},{"key":"key-10.3934\/microbiol.2021007-67","doi-asserted-by":"crossref","unstructured":"Weng CH, Saal A, Butt WWW, et al. (2020) Bacillus Calmette-Gu\u00e9rin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: A cohort study.&nbsp;<i>Epidemiol Infect<\/i>&nbsp;148: e140.","DOI":"10.1017\/S0950268820001569"},{"key":"key-10.3934\/microbiol.2021007-68","doi-asserted-by":"crossref","unstructured":"Kirov S (2020) Association Between BCG Policy is Significantly Confounded by Age and is Unlikely to Alter Infection or Mortality Rates.&nbsp;<i>medRxiv<\/i>&nbsp;(April).","DOI":"10.1101\/2020.04.06.20055616"},{"key":"key-10.3934\/microbiol.2021007-69","doi-asserted-by":"crossref","unstructured":"Hensel J, McGrail D, McAndrews K, et al. (2020) Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing.&nbsp;<i>medRxiv<\/i>&nbsp;.","DOI":"10.1101\/2020.04.08.20056051"},{"key":"key-10.3934\/microbiol.2021007-70"},{"key":"key-10.3934\/microbiol.2021007-71"},{"key":"key-10.3934\/microbiol.2021007-72","unstructured":"ClinicalTrials.gov.&nbsp;BCG Vaccine for Health Care Workers as Defense Against COVID 19 (2020) ."},{"key":"key-10.3934\/microbiol.2021007-73"},{"key":"key-10.3934\/microbiol.2021007-74","unstructured":"Adesanya O, Ebengho I (2020) Possible Correlation between Bacillus Calmette Gu\u00e9rin (BCG) Vaccination Policy and SARS-Cov-2 Transmission, Morbidity and Mortality Rates: Implications for the African Continent.&nbsp;<i>J Infect Dis Epidemiol<\/i>&nbsp;6: 137."}],"container-title":["AIMS Microbiology"],"original-title":[],"link":[{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/microbiol.2021007?viewType=html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T12:10:45Z","timestamp":1671106245000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/microbiol.2021007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3934\/microbiol.2021007","relation":{},"ISSN":["2471-1888"],"issn-type":[{"value":"2471-1888","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}